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Abstract: This work aimed to study the association between fibrinolytic/endothelial cell function and inflamma-
tory markers in chronic kidney disease (CKD) patients undergoing hemodialysis (HD) and recombinant human
erythropoietin (rhEPO) therapies, and its relationship with the type of vascular access (VA) used for the HD pro-
cedure. As fibrinolytic/endothelial cell function markers we evaluated plasminogen activator inhibitor type-1 (PAI-
1), tissue plasminogen activator (tPA) and D-dimers, and as inflammatory markers; C-reactive protein (CRP),
soluble interleukin (IL)-2 receptor (s-IL2R), IL-6 and serum albumin levels. The study was performed in 50 CKD
patients undergoing regular HD, 11 with a central venous dialysis catheter (CVC) and 39 with an arteriovenous fi-
stula (AVF), and in 25 healthy controls. Compared to controls, CKD patients presented with significantly higher
levels of CRP, s-IL2R, IL-6 and D-dimers, and significantly lower levels of PAI-1. The tPA/PAI-1 ratio was signifi-
cantly higher in CKD patients. We also found statistical significant correlations in CKD patients between D-dimers
levels and inflammatory markers: CRP, albumin, s-IL2R and IL-6. When comparing the two groups of CKD pa-
tients, we found that those with a CVC presented statistically significant lower levels of hemoglobin concentration
and albumin, and higher levels of CRP, IL-6, D-dimers and tPA. Our results showed an association between fibri-
nolytic/endothelial cell function and increased inflammatory markers in CKD patients. The increased levels of D-
dimer, tPA and inflammatory markers in CKD patients using a CVC, led us to propose a relationship between the
type of VA chosen for HD, and the risk of thrombogenesis.  (J Vasc Access 2008; 9: 248-53)
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INTRODUCTION
A successful hemodialysis (HD) procedure requires
a functional vascular access (VA). Unfortunately, no
major advances in the field of HD VA have been ob-
served for the past 30 yrs,  and this has probably
contributed to VA dysfunction as being one of the
most important causes of morbidity in the HD pop-
ulation (1). Access-related problems are responsible
for 50% of the hospitalizations of HD patients (2).
Currently, there are three main forms of HD VA: ar-
teriovenous fistula (AVF), polytetrafluoroethylene
(PTFE) graft, and central venous catheter (CVC).
Each of these forms has its own specific problems.
AVF is the first choice for VA in patients undergoing
chronic HD due to its relative low risk of infection
and thrombosis. However, this type of VA has two ma-
jor complications: initial failure to mature (primary
non-function) and a later venous stenosis followed by
thrombosis (3). A PTFE graft is relatively easy to
placeand ready to use; however, extremely high rates
of stenosis, thrombosis, and infection are reported
for this VA (4). CVC is the least desirable method of
HD access. In a sense, every CVC placement repre-
sents a failure: failure to prepare a native AVF in
advance of initiating dialysis; failure to detect fail-
ing AV access and maintain its function, or create
a suitable alternative. Nevertheless, catheters are
an unavoidable necessity for many patients who
do not have functional AV access for any reason.
In recent years, the use of CVCs has increased in
both acute and chronic uremic patients, and this
could underlie the increased morbidity and mor-
tality observed in these patients. The type of in-
sertion and the management of a CVC can lead to
several complications, namely infections and
thrombosis (5). 
An inflammatory stimulus triggers the synthesis of
acute phase proteins, namely C-reactive protein
(CRP), a prominent marker of inflammatory re-
sponse in the general population and in chronic
kidney disease (CKD) patients (6-8). CRP increases
significantly in hemodialyzed patients, as compared
with healthy controls (8, 9) and this rise appears to
be a common feature in hemodialyzed patients.
Chronic inflammation is also associated with ather-
osclerotic cardiovascular disease (CVD). CRP has
been proposed as a new risk marker for CVD events;
the high rate of morbidity and mortality observed in
aemodialyzed patients (10, 11) could reflect the over-
lapping of these proinflammatory conditions and/or
the inflammatory process in CKD patients favoring
CVD events. 
CKD patients undergoing HD have been also associ-
ated with complex hemostatic disorders, clinically ex-
pressed with both bleeding tendency and hypercoag-
ulability, though its etiology is poorly understood. A
disturbance in fibrinolysis was reported in CKD pa-
tients; however, studies of different fibrinolysis pa-
rameters in regularly dialyzed patients have yielded
conflicting results, with some indicating suppressed
fibrinolysis and others showing increased fibrinolysis
(12). Several hemostatic proteins are also considered
endothelial cell function markers, namely plasmino-
gen activator inhibitor 1 (PAI-1) and tissue plasmino-
gen activator (tPA), being both secreted by endothe-
lial cells.
There are a considerable number of studies re-
garding the association of the type of VA with in-
flammatory markers and fibrinolytic/endothelial
cell dysfunction (13, 14). However, only a few have
investigated simultaneously inflammatory and fib-
rinolytic/endothelial cell dysfunction markers. 
This work aimed to study the association between fib-
rinolytic/endothelial cell function and inflamma-
tory markers in CKD patients undergoing HD and
recombinant human erythropoietin (rhEPO) ther-
apies, and its relationship with the type of VA used
for the HD procedure.
MATERIALS AND METHODS 
Subjects 
We studied 50 CKD patients undergoing regular HD
(32 males, 18 females; mean age 64.5 ± 15.4 yrs)
and rhEPO therapy. These patients were recruited,
after giving informed consent, from two HD clinics
during a 1-year period. In 11 patients, the VA used
for HD was a tunneled CVC, and in 39 patients it was
an AVF. The CVC were used for a median period of
36 months (12-84 months). The incidence of VA in-
fection in the unit is 5.6%.
CKD patients were undergoing therapeutic HD three
times per week, for 3-5 hr, for a median period of 36
months. All patients used the high-flux polysulfone
FX-class dialyzers of Fresenius, 25 with FX60, 23 with
FX80 and 2 with the FX100 dialyzer type. 
Patients with autoimmune disease, malignancy,
hematological disorders, and acute or chronic in-
fection were excluded. We also excluded patients
that presented, at the time of analysis with a positive
blood culture result.
The control group included 25 healthy volunteers (8
males, 17 females; mean age 47.81 ± 14.69 yrs) pre-
senting normal hematological and biochemical val-
ues, with no history of renal or inflammatory dis-
eases, and, as far as possible, age and gender
matched with CKD patients.
Assays
Blood samples were drawn from fasting controls and
in the case of the hemodialyzed patients before the
second dialysis session of the week. Blood samples
were collected with and without anticoagulant [eth-
ylenediamine tetraacetic acid (EDTA)], in order to
obtain whole blood, plasma and serum.  
Hemoglobin (Hb) concentration and white blood
cell (WBC) count were measured using an auto-
matic counter (Sysmex K1000, Hamburg, Germany);
differential leukocyte counts were evaluated in
Wright-stained blood films. Serum CRP was meas-
ured by immunoturbidimetry (CRP latex HS Roche
kit, Roche Diagnostics) and an enzyme-linked im-
munoabsorbent assay was used for measurement of
serum soluble interleukin 2 receptor (s-IL2R) (hu-
man IL-2 SRa, R&D systems, MN, USA). Serum al-
bumin levels were measured using a colorimetric as-
say end-point method (Albumin Plus; Roche GmbH,
Mannheim, Germany). Serum IL-6 levels were quan-
tified using the BDTM Cytometric Bead Array Hu-
man Th1/Th2 Cytokine Kit II (BD Biosciences, USA,
San Diego), and analyzed using the BDTM CBA soft-
ware. Plasma levels of PAI-1, tPA and D-dimers were
evaluated by enzyme-linked immunoabsorbent as-
says (TintElize PAI-1, TintElize tPA and TintElize D-
dimer, Biopool-Trinity Biotech Company, respec-
tively). Serum iron concentration was determined
using a colorimetric method (Iron, Randox Labora-
tories Ltd, Northern Ireland, UK), whereas serum
ferritin and serum transferrin were measured by im-
munoturbidimetry (Ferritin, Laboratories Ltd,
Northern Ireland, UK; Transferrin, Laboratories
Ltd, Northern Ireland, UK). Transferrin saturation
(TS) was calculated by the formula: TS (%) = 70.9 x
serum iron concentration in (µg/dL) / serum trans-
ferrin concentration in (mg/dL).  
Data analysis
For statistical analysis, we used the Statistical Package
for Social Sciences, version 14.0. Kolmogorov
Smirnov statistics were used to evaluate sample nor-
mality distribution. Comparisons between groups
were performed using the Kruskal-Wallis test and
the Mann-Whitney U test (data with a non-Gaussian
distribution) or one-way ANOVA supplemented with
Tukey’s HSD post-hoc test (data with a Gaussian dis-
tribution). Spearman’s rank correlation coefficient
was used to evaluate relationships between sets of
data. Adjustment of statistical differences for con-
founding factors (comorbidity, age, sex and body
mass index) was performed by analysis of covari-
ance, after log transformation of variavel (when nec-
essary). Multiple regression analysis using the step-
wise method was used to determine independent
factors affecting D-dimers levels. Significance was
accepted at p<0.05. 
RESULTS
Tables I and II show rhEPO doses, hematological
data, fibrinolytic and inflammatory cell markers,
dialysis adequacy parameters, and nutritional and
iron status, for controls and CKD patients.  
Compared to controls, CKD patients presented with
significantly higher counts of WBC and neutrophils,
and higher levels of ferritin, CRP, s-IL2R, IL-6 and D-
dimers. CKD patients also presented with signifi-
cantly lower levels of Hb and PAI-1. The tPA/PAI-1
ratio was significantly higher for CKD patients.
When comparing the two groups of CKD patients, we
found that those with a CVC VA presented with sta-
tistically significant lower levels of Hb, TS and albu-
min, and higher levels of neutrophils, CRP, IL-6, D-
dimers and tPA. Statistical significance remained
after adjustment for the confounding factors. A
trend to higher rhEPO doses to achieve target Hb
levels (11-12 g/dL) was found in CKD patients using
a CVC as VA (Tab. I). 
We also found in CKD patients, statistically significant
correlations between D-dimer levels and inflamma-
tory markers: CRP, albumin, s-IL2R and IL-6 (Fig. 1).
TABLE I - HEMATOLOGICAL DATA, FIBRINOLYTIC AND INFLAMMATORY CELL MARKERS, DIALYSIS ADEQUACY 
PARAMETERS, AND NUTRITIONAL AND IRON STATUS IN CONTROLS AND CKD PATIENTS
Healthy Controls All CKD Patients
(n=25) (n=50)
Weekly rhEPO (IU/Kg) dose – 271.29 (79.22-577.29)
Hb (g/dL) 14.12 ± 1.27 11.06 ± 1.77 a)
WBC (x 109/L) 5.80 ± 1.60  10.03 ± 4.54 a)
Neutrophils (x 109/L) 3.00 ± 1.00 6.08 ± 3.01 a)
Platelets (x 109/L) 242.12 ± 78.57 212.48 ± 98.39
CRP (mg/dL) 1.75 (0.76-4.70) 5.75 (1.90-14.00) a)
s-IL2R (nmol/L) 758.83 ± 234.95 4199.94 ± 1762.82 a)
IL-6 (pg/mL) 1.90 (0-3.75) 7.8 (3.85-15.05) a)
Albumin (g/dl) – 3.84 ± 0.42
D-dimer (ng/mL) 63.50 (51.94-77.41) 157.26 (97.72-417.09) a)
tPA (ng/mL) 4.72 ± 2.95 4.60 ± 3.57
PAI-1 (ng/mL) 58.17 ± 24.25 42.85 ± 23.53 a)
tPA/PAI-1 ratio 0.09 ± 0.06 0.14 ± 0.11 a)
Transferrin saturation (%) 21.83 ± 7.97 22.89 ± 11.06
Ferritin (ng/mL) 85.10 (37.88-123.95) 389.65 (186.58-604.90)a)
Ktv – 1.59 ± 0.29
Urea reduction (%) – 26.98 ± 8.53
Protein catabolic rate (g/Kg/day) – 0.85 ± 0.04
*Results are presented as mean ± one standard deviation or as median values (inter-quartile range). a) p<0.05, vs. controls
TABLE II - HEMATOLOGICAL DATA, FIBRINOLYTIC AND INFLAMMATORY CELL MARKERS, DIALYSIS ADEQUACY 
PARAMETERS, AND NUTRITIONAL AND IRON STATUS ACCORDING TO THE TYPE OF VASCULAR ACCESS
CKD patients with AVF CKD patients with CVC
(n=39) (n=11)
Weekly rhEPO (IU/Kg) dose 156.01 (56.82-582.52) 456.12 (102.56-575.54)
Hb (g/dL) 11.27 ± 1.86 10.30 ± 1.18 a)
WBC (x 109/L) 10.11 ± 4.57 9.77 ± 4.64 
Neutrophils (x 109/L) 5.90 ± 2.96 6.71 ± 3.27 a)
Platelets (x 109/L) 203.17 ± 85.19 245.45 ± 135.36
CRP (mg/dL) 4.10 (1.80-11.02) 6.46 (4.10-39.70) a)
s-IL2R (nmol/L) 4177.78 ± 1745.00 4278.51 ± 1909.72 
IL-6 (pg/mL) 5.95 (3.80-12.40) 14.00 (5.70-30.20) a) 
Albumin (g/dl) 3.94 ± 0.36 3.51 ± 0.46 a)
D-dimer (ng/mL) 141.63 (89.13-214.75) 632.88 (339.75-967.88) a)
tPA (ng/mL) 3.94 ± 2.21 6.99 ± 5.99 a)
PAI-1 (ng/mL) 40.74 ± 22.37 50.37 ± 27.06
tPA/PAI-1 ratio 0.14 ± 0.12 0.15 ± 0.08 
Transferrin saturation (%) 25.19 ± 10.84 14.70 ± 7.63 a)
Ferritin (ng/mL) 454.66 (246.00-634.00) 374.00 (120.00-452.00)
Ktv 1.63 ± 0.27 1.50 ± 0.36
Urea reduction (%) 25.78 ± 7.01 31.12  ± 11.97
Protein catabolic rate (g/Kg/day) 0.87 ± 0.04 0.81 ± 0.03
*Results are presented as mean ± one standard deviation or as median values (inter-quartile range). a) p<0.05 vs. CKD patients
with an AVF
Fig. 1 - Correlation between
D-dimer levels and inflam-
matory markers in CKD pa-
tients: CRP (A), albumin
(B), s-IL2R (C) and IL-6
(D). Circles represent pa-
tients with an AVF and tri-
angle patients with a CVC.
Multiple regression analysis identified the weight
(β=-0.367; p=0.03), neutrophil count (β=0.399;
p=0.001) and s-IL2R (β=0.279; p=0.022) as the in-
dependent variables significantly associated with D-
dimers (R2=0.427).
DISCUSSION
CKD patients showed anemia, which, as reported in
the literature (15), is mainly determined by the rate
of renal insufficiency; and therefore, by the reduc-
tion in the renal secretion of erythropoietin. Addi-
tionally, CKD patients undergoing HD treatment
presented with leukocytosis, neutrophilia and in-
creased levels of IL-6, s-IL2R and CRP inflammatory
molecules in the serum, confirming the presence of
an inflammatory process.
In our CKD patients, we found low levels of PAI-1 and
normal tPA plasma levels, suggesting that endothe-
lial and fibrinolytic functions are not apparently al-
tered in these patients (16). However, the tPA/PAI-
1 ratio was increased in our CKD patients, and the
increase in this ratio has been described as a novel
risk marker for recurrent myocardial infarction (17).
We also found an increase in D-dimers in our pa-
tients; however, it is uncertain if the higher fibrin
fragment D-dimer value in CKD patients is a result of
a higher activation of coagulation or of fibrinolysis. 
The higher tPA/PAI-1 ratio in CKD patients under-
going HD could suggest a higher fibrinolysis in these
patients because only PAI-1 presented a significantly
lower value. However, we did not measure fibrinolytic
activity. On the other hand, an interesting cross-talk
has been proposed to exist between inflammation
and coagulation (18). The higher inflammatory sta-
tus observed in CKD patients could actually under-
lie coagulation activation. For instance, CRP is
known to promote  tissue factor synthesis (19), a
potent procoagulant, by monocytes. The correla-
tions and the multiple regression analysis that we
found between D-dimer levels and inflammatory
markers, underlie this hypothesis. From that per-
spective, the higher D-dimer levels in the CKD pa-
tients can also be observed as a marker of the in-
flammatory process in these patients. 
When comparing our results to that previously de-
scribed, we found some conflicting results, namely
for PAI-1 that was been described to be increased
(20, 21) or normal (22). For tPA, we found descrip-
tions of normal values, as we found in this work,
and other describing higher levels (20). These dif-
ferences could be due to the difference between the
studied CKD patient population and due to the type
of kit used in the laboratorial evaluation. Increase D-
dimer and tPA/PAI-1 ratio is the most consistent
finding in most of the studies. 
When we analyzed the results of the studied param-
eters according to the type of VA used, the CVC pa-
tients showed lower albumin and Hb values, and
higher tPA, D-dimers, CRP and IL-6 levels as com-
pared to those with an AVF, suggesting that these pa-
tients have an even higher inflammatory process.
Our results also showed in CKD patients using a
CVC as VA that they seem to require a higher rhEPO
dose to achieve the target Hb levels, suggesting also
cross-talk of erythropoiesis with inflammation. 
It is important to note that we measured tPA antigen,
which reflects both active free tPA and inert tPA
bound to inhibitor(s) (23). Therefore, higher tPA
values are not synonymous with higher activated fib-
rinolysis; higher t-PA values could result from en-
dothelial dysfunction (23). Although tPA was higher
in CVC patients, the tPA/PAI-1 ratio remained un-
changed suggesting a similar activation of coagula-
tion and fibrinolysis. The higher D-dimer values are
more likely to result from enhanced coagulation
probably linked to a higher inflammatory stimulus,
than to a higher fibrinolysis, as only a trend to higher
PAI-1 levels was observed in CVC patients.
In summary, our results showed a relationship be-
tween hemostasis and increased inflammatory mark-
ers in CKD patients. The increased levels of D-dimer,
tPA and inflammatory markers in CKD patients using
a CVC, led us to propose a relationship between the
type of VA chosen for HD, and the risk of thrombo-
genesis. It seems reasonable to assume that these
patients could present with an increased risk for
CVD events. 
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